Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Mitwasi, N."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Abdelfatah Saleh Hassan, H. A., Mitwasi, N., Ullrich, M., Kubeil, M., Toussaint, M., Deuther-Conrad, W., Neuber, C., Arndt, C., Rodrigues Loureiro, L. R., Kegler, A., González Soto, K. E., Belter, B., Rössig, C., Pietzsch, J., Frenz, M., Bachmann, M., Feldmann, A.
Publikováno v:
Frontiers in Immunology 14(2023), 1166169
Glioblastoma (GBM) is still an incurable tumor that is associated with high recurrence rate and poor survival despite the current treatment regimes. With the urgent need for novel therapeutic strategies, immunotherapies, especially chimeric antigen r
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kegler, A., Drewitz, L., Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., Neuber, C., González Soto, K. E., Bartsch, T., Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Szigeti, K., Bergmann, R., Feldmann, A., Bachmann, M.
Publikováno v:
Frontiers in Immunology 14(2023), 1204543
The COVID-19 pandemic caused by SARS-CoV-2 led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options, which can win the race against new emerging variants of concern. Here, we descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::fdce3d0afa5c96d96efc48a7e94d2f77
https://www.hzdr.de/publications/Publ-37085-1
https://www.hzdr.de/publications/Publ-37085-1
Publikováno v:
Tumor Immunology meets Oncology (TIMO) XVII 2023 Halle, 20.-22.04.2023, Halle, Germany
Novel immunotherapeutic approaches such as chimeric antigen receptor (CAR)-expressing immune cells are showing promising results against cancer. Among these are the CAR Natural Killer (NK) cells that can be produced from either established cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::d6fdc8488e3c7661e97f1debd4d4bfe6
https://www.hzdr.de/publications/Publ-36995-1
https://www.hzdr.de/publications/Publ-36995-1
45P The RevCAR T cell platform: A switchable and combinatorial therapeutic strategy for glioblastoma
Autor:
Mitwasi, N., Hassan, H., Arndt, C., Loureiro, L., Neuber, C., Kegler, A., Kubeil, M., Toussaint, M., Deuther-Conrad, W., Bachmann, M., Feldmann, A.
Publikováno v:
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Autor:
Jureczek J, Feldmann A, Bergmann R, Arndt C, Berndt N, Koristka S, Loureiro LR, Mitwasi N, Hoffmann A, Kegler A, Bartsch T, Bachmann M
Publikováno v:
OncoTargets and Therapy, Vol Volume 13, Pp 5515-5527 (2020)
Justyna Jureczek,1– 3 Anja Feldmann,3 Ralf Bergmann,3,4 Claudia Arndt,3 Nicole Berndt,3 Stefanie Koristka,3 Liliana Rodrigues Loureiro,3,5 Nicola Mitwasi,3 Anja Hoffmann,3 Alexandra Kegler,1– 3 Tabea Bartsch,3 Michael Bachmann1– 3,5,6 1German C
Autor:
Loureiro, L. R., Bergmann, R., Wodtke, R., Brandt, F., Arndt, C., González Soto, K. E., Mitwasi, N., Kegler, A., Bartsch, T., Drewitz, L., Máthé, D., Feldmann, A., Bachmann, M.
Publikováno v:
International Conference on Lymphocyte Engineering: ICLE 2022, 31.03.2022, Munich, Germany
Chimeric antigen receptor (CAR) T-cells are undoubtedly a promising approach in cancer immunotherapy. Nevertheless, mild to severe toxicities are associated with this approach including on-target/off-tumor effects and cytokine release syndrome. Aimin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::82ee679d55efbb300cac99b2e78b78d4
https://www.hzdr.de/publications/Publ-33876-1
https://www.hzdr.de/publications/Publ-33876-1
Autor:
Loureiro, L. R., Neuber, C., Hoffmann, L., Kubeil, M., Arndt, C., Mitwasi, N., Kegler, A., Bergmann, R., Feldmann, A., Bachmann, M.
Publikováno v:
Australian Society of Molecular Imaging (ASMI) Conference 2022, 06.-07.10.2022, Melbourne, Australia
Chimeric antigen receptor (CAR) T-cells are unquestionably considered one of the most promising approaches in cancer immunotherapy. Nonetheless, mild to severe toxicities are associated with this approach which include e.g. on-target/off-tumour toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::f2b505dae55a7fe127df79c2a7504987
https://www.hzdr.de/publications/Publ-35718-1
https://www.hzdr.de/publications/Publ-35718-1
Autor:
Bartsch, T., Arndt, C., González Soto, K. E., Wodtke, R., Brandt, F., Loureiro, L. R., Mitwasi, N., Kegler, A., Feldmann, A., Bachmann, M.
Publikováno v:
TUMOR IMMUNOLOGY MEETS ONCOLOGY (TIMO) XVI 2022 HALLE, 07.-09.07.2022, Halle, Deutschland
As next generation for CAR T cells, adaptor CAR platforms have been developed, which are designed to improve safety, but at the same time maintain the high efficiency of the CAR T cell approach. In our lab, we developed the UniCAR system, which consi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::7de400d0e45c769deb9eb2040bc3f571
https://www.hzdr.de/publications/Publ-35749-1
https://www.hzdr.de/publications/Publ-35749-1